Your session is about to expire
← Back to Search
Endoxifen for Hormone-Receptor-Positive Cancer
Study Summary
This trial is testing the safety and effectiveness of the drug endoxifen in individuals with hormone receptor positive solid tumors. Eligible participants must be 18 years or older and have had at least one prior chemotherapy and hormonal regimen for metastatic disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a cancer that started in my reproductive organs.My tumor is positive for estrogen or progesterone receptors.I have cancer spread to my spine or near vital organs that hasn't been treated.I have breast cancer and have been treated with tamoxifen or aromatase inhibitors.I have had deep vein thrombosis but am not on blood thinners.My organ and bone marrow functions are normal or adequate.I agree to use effective birth control methods.My HER2+ breast cancer has worsened after at least one treatment.My condition worsened after receiving standard treatment.I have recovered from side effects of my previous cancer treatments.I am 18 years old or older.I have a desmoid tumor.My brain metastases have been stable for 3+ months without needing steroids or seizure meds.My cancer is a solid tumor, including certain types of breast cancer.I have breast cancer and have received at least one chemotherapy treatment for it when it spread.I can take care of myself but might not be able to do heavy physical work.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants still being invited to participate in this investigation?
"As per data listed on the clinicaltrials.gov website, this medical trial is no longer engaging in recruitment efforts. This research was initially published on March 1st 2011 and last edited on December 1st 2022. Although this study has since ended its search for patients, 16 other trials are still looking to enroll individuals at present."
Are there any health risks associated with Z-Endoxifen use?
"Our assessment of Z-Endoxifen's safety is rated at 1 due to its Phase 1 status, meaning there are limited studies demonstrating both its efficacy and security."
Share this study with friends
Copy Link
Messenger